Merçé Boada
Impact in
- Psychiatry and Mental health top 0.1%
- Dementia and Cognitive Impairment Research
- Schizophrenia research and treatment
- Physiology top 0.02%
- Alzheimer's disease research and treatments
Papers in
-
- Dementia and Cognitive Impairment Research 269
- Physiology 219
- Alzheimer's disease research and treatments 212
- Co-authors
- Sid Gilman (2 shared papers)Lachlan Kirby (2 shared papers)Agustín Ruiz Laza (74 shared papers)Bruno Dubois (14 shared papers)Lluís Tárraga (55 shared papers)Isidró Ferrer (7 shared papers)Maria Jesus Rey (4 shared papers)Montserrat Alegret (46 shared papers)
- Journals
- Alzheimer s & Dementia (85 papers)Journal of Alzheimer s Disease (48 papers)Alzheimer s Research & Therapy (31 papers)Scientific Reports (13 papers)Neurobiology of Aging (12 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Merçé Boada
426 papers receiving 29.9k citations
Merçé Boada's Hit Papers
Peers
Comparison fields: 5 of 205
- Psychiatry and Mental health 10k
- Physiology 13.9k
- Neurology 2.3k
- Neurology 1.8k
- Genetics 2.7k
Countries citing papers authored by Merçé Boada
This map shows the geographic impact of Merçé Boada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Merçé Boada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Merçé Boada more than expected).
Fields of papers citing papers by Merçé Boada
This network shows the impact of papers produced by Merçé Boada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Merçé Boada. The network helps show where Merçé Boada may publish in the future.
Co-authors
The 25 scholars most cited alongside Merçé Boada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 459 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease Hit paper breakdown → | 2013 | 3486 |
| 2 | Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing Hit paper breakdown → | 2019 | 2140 |
| 3 | New insights into the genetic etiology of Alzheimer’s disease and related dementias Hit paper breakdown → | 2022 | 1531 |
| 4 | Analysis of shared heritability in common disorders of the brain Hit paper breakdown → | 2018 | 1477 |
| 5 | Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease Hit paper breakdown → | 2014 | 1332 |
| 6 | Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Hit paper breakdown → | 2003 | 1156 |
| 7 | Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial Hit paper breakdown → | 2005 | 1108 |
| 8 | Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease Hit paper breakdown → | 2018 | 878 |
| 9 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease Hit paper breakdown → | 2017 | 764 |
| 10 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 11 | Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease Hit paper breakdown → | 2017 | 521 |
| 12 | 2004 | 501 | |
| 13 | A Phase II Trial of Tideglusib in Alzheimer's Disease Hit paper breakdown → | 2015 | 457 |
| 14 | A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease Hit paper breakdown → | 2017 | 456 |
| 15 | Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease Hit paper breakdown → | 2019 | 448 |
| 16 | Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies Hit paper breakdown → | 2015 | 373 |
| 17 | 2014 | 300 | |
| 18 | 2016 | 253 | |
| 19 | Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation Hit paper breakdown → | 2024 | 234 |
| 20 | 2015 | 221 |
About Merçé Boada
Merçé Boada is a scholar working on Psychiatry and Mental health, Physiology, Neurology, Genetics and Neurology, having authored 459 papers that have together received 30.7k indexed citations. Recurring topics across this work include Dementia and Cognitive Impairment Research (269 papers), Alzheimer's disease research and treatments (212 papers), Genetic Associations and Epidemiology (20 papers), Amyotrophic Lateral Sclerosis Research (17 papers), Parkinson's Disease Mechanisms and Treatments (10 papers), Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Intracerebral and Subarachnoid Hemorrhage Research (6 papers) and Genetic Neurodegenerative Diseases (5 papers). The work is most often cited by research in Psychiatry and Mental health (10k citations), Physiology (13.9k citations), Neurology (2.3k citations), Neurology (1.8k citations) and Genetics (2.7k citations). Merçé Boada has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Sid Gilman, Lachlan Kirby, Agustín Ruiz Laza, Bruno Dubois, Lluís Tárraga, Isidró Ferrer, Maria Jesus Rey, Montserrat Alegret, Jean‐Marc Orgogozo and Nick C. Fox. Their work appears in journals such as Alzheimer s & Dementia, Journal of Alzheimer s Disease, Alzheimer s Research & Therapy, Scientific Reports and Neurobiology of Aging.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.